Innate Pharma (IPHA) Expected to Post Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) is expected to be releasing its Q2 2026 results before the market opens on Thursday, September 17th. Analysts expect Innate Pharma to announce earnings of ($0.2946) per share and revenue of $6.3530 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, September 17, 2026 at 8:00 AM ET.

Innate Pharma Stock Performance

NASDAQ:IPHA opened at $1.86 on Wednesday. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.71. The stock’s 50-day moving average price is $1.97 and its 200-day moving average price is $1.74.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IPHA. Weiss Ratings upgraded Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. HC Wainwright increased their target price on Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Finally, Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.67.

About Innate Pharma

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.